• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Evotec, Sanofi ink agreement for multi-component alliance

Evotec, Sanofi ink agreement for multi-component alliance

March 20, 2015
CenterWatch Staff

Evotec, a drug discovery alliance and development partnership company based in Germany, has signed an agreement for a major multi-component strategic alliance over the next five years with Sanofi. The transaction is expected to close March 31.

The collaboration will result in a minimum guaranteed commitment from Sanofi to Evotec of $270 million, including more than $43 million upfront in cash. The five-year agreement includes initiatives with both of Evotec's two business segments (EVT Execute and EVT Innovate).

Following its strategic growth plans, Evotec will expand its capabilities in drug discovery by integrating a state-of-the-art facility and more than 200 employees in Toulouse, France. Evotec will integrate the Toulouse capacities into its global drug discovery infrastructure and offering. The expanded capabilities will serve to support collaborative research in drug discovery from screening to identification of preclinical candidates with Evotec's Pharma, biotech, venture capital and academic partners.

Evotec will provide a broad range of long-term drug discovery services to Sanofi. This agreement is centered on the core small-molecule discovery platforms in Toulouse. In addition, Evotec will assume management of Sanofi's global screening compound library.

In an open innovation initiative, the companies will combine their libraries and offer them for screening to Evotec's business partners. This creates one of the largest sources of starting points for drug discovery, with approximately 1.7 million compounds available to screen.

The definitive agreement defines the conditions under which Evotec and Sanofi intend to jointly progress a portfolio of primarily oncology related projects, including five advanced, preclinical projects and further discovery-stage assets, to IND status or other value inflection points before partnering them.

Sanofi and Evotec aim at further energizing and accelerating the translation of excellent science from academic institutions to Pharma. In a joint effort, Evotec will scout and incubate projects generated in France into the pipeline of Evotec's Cure X/Target X strategy.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing